scholarly journals MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy

Oncotarget ◽  
2016 ◽  
Vol 7 (38) ◽  
pp. 61166-61182 ◽  
Author(s):  
XiaoRong Zhong ◽  
GuiQin Xie ◽  
Zhang Zhang ◽  
Zhu Wang ◽  
Yu Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Target Gene ◽  
Adjuvant Endocrine Therapy ◽  
Prognostic Biomarkers ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial

2014 ◽  
Vol 50 (13) ◽  
pp. 2190-2200 ◽  
Author(s):  
Duveken B.Y. Fontein ◽  
Ayoub Charehbili ◽  
Johan W.R. Nortier ◽  
Elma Meershoek-Klein Kranenbarg ◽  
Judith R. Kroep ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Breast Cancer Patients ◽  
Neoadjuvant Endocrine Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document